Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 1/20 | 0.44 |
| ▸ | NAMPT | P43490 | 7/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.42 |
| ▸ | USP2 | O75604 | 3/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.40 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.40 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.40 |
| ▸ | SPTLC2 | O15270 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL484814 | 0.87 | TAS1R3 (0.46) | CTSSNAMPTCYP3A4USP2CYP1A2 | |
| SCHEMBL484828 | 0.85 | EPHX2 (0.46) | CTSSCYP3A4USP2CYP1A2ALDH1A1 | |
| SCHEMBL484792 | 0.84 | CYP3A4 (0.55) | CYP3A4USP2CYP1A2ALDH1A1TSHR | |
| SCHEMBL484356 | 0.83 | ALDH1A1 (0.48) | ALDH1A1TAS1R3TAS1R1TAS1R2SPTLC2 | |
| SCHEMBL484657 | 0.83 | TAS1R3 (0.44) | CTSSNAMPTALDH1A1TAS1R3TAS1R1 | |
| SCHEMBL484537 | 0.83 | EPHX2 (0.46) | CTSSNAMPTCYP3A4USP2CYP1A2 | |
| SCHEMBL484992 | 0.83 | ALDH1A1 (0.46) | ALDH1A1CNR2EPHX2TAS1R3TAS1R1 | |
| SCHEMBL2815468 | 0.82 | ALDH1A1 (0.47) | NAMPTALDH1A1TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL484789 | 0.82 | CYP3A4 (0.43) | NAMPTCYP3A4USP2CYP1A2ALDH1A1 | |
| SCHEMBL484543 | 0.82 | TAS1R3 (0.44) | ALDH1A1TAS1R3TAS1R1TAS1R2SPTLC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130231327-A1 | Substituted Spiro-Amide Compounds | GRUENENTHAL GMBH (DE) | 2013-09-05 | — | — | US | claimed |
| US-8455475-B2 | Substituted spiro-amide compounds | GRUENENTHAL GMBH (DE) | 2013-06-04 | — | — | US | claimed |
| US-20100249095-A1 | Substituted Spiro-amide Compounds | GRUENENTHAL GMBH (DE) | 2010-09-30 | — | — | US | claimed |
| US-20130231327-A1 | Substituted Spiro-Amide Compounds | GRUENENTHAL GMBH (DE) | 2013-09-05 | — | — | US | disclosed |
| US-8455475-B2 | Substituted spiro-amide compounds | GRUENENTHAL GMBH (DE) | 2013-06-04 | — | — | US | disclosed |
| EP-2411381-A1 | SUBSTITUTED SPIRO-AMIDE COMPOUNDS | Grünenthal GmbH (DE) | 2012-02-01 | — | — | EP | disclosed |
| US-20100249095-A1 | Substituted Spiro-amide Compounds | GRUENENTHAL GMBH (DE) | 2010-09-30 | — | — | US | disclosed |
| WO-2010108651-A1 | SUBSTITUTED SPIRO-AMIDE COMPOUNDS | Grünenthal GmbH (DE) | 2010-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130231327-A1 | Substituted Spiro-Amide Compounds | BDKRB1, BDKRB2, REN | CTSS 3024/4885NAMPT 2232/4885CYP3A4 3781/4885 |
| US-20100249095-A1 | Substituted Spiro-amide Compounds | BDKRB1, BDKRB2, REN | CTSS 3024/4885NAMPT 2232/4885CYP3A4 3781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.